Showing 1521-1530 of 2656 results for "".
- Pfizer, BioNTech’s mRNA-Based COVID-19 Vaccine Shows Promise in Second Studyhttps://modernod.com/news/pfizer-biontechs-mrna-based-covid-19-vaccine-shows-promise-in-second-study/2478049/Pfizer and BioNTech announced that the most advanced of four COVID-19 vaccine candidates from their BNT162 mRNA-based vaccine program demonstrated the ability to elicit high SARS-CoV-2 neutralising titers after the second dose in an ongoing phase 1/2 study in Germany. The results, which were publ
- Synairgen’s Inhaled Interferon Beta Cuts Chance of Developing Severe COVID-19 Diseasehttps://modernod.com/news/synairgens-inhaled-interferon-beta-cuts-chance-of-developing-severe-covid-19-disease/2478043/Synairgen announced Monday that its inhaled formulation of interferon beta, dubbed SNG001, significantly reduced the chance of developing severe disease compared to placebo in hospitalized COVID-19 patients. Chief study investigator Tom Wilkinson remarked “the results confirm our belief tha
- Trump Health Official Says COVID Patients Should Not Re-Test. ‘It’s clogging up the system.’https://modernod.com/news/trump-health-official-says-covid-patients-should-not-re-test-its-clogging-up-the-system/2478038/The Trump administration plans to release guidance that non-hospitalized patients who test positive for COVID-19 do not need a second test to confirm they are clear of the virus, according to a FierceHealthcare
- COVID-19 Has Flipped the Physician Job Search to a Seller’s Market, Recruiters Sayhttps://modernod.com/news/covid-19-has-flipped-the-physician-job-search-to-a-sellers-market-recruiters-say/2478020/Job opportunities for doctors have dried up quite a bit in wake of the COVID-19 pandemic, at least in the short term, according to an annual report from physician search firm Merritt Hawkins, according to a FierceHealthcare
- STAAR Surgical’s EVO Viva Presbyopia Correcting Lens Receives CE Mark Approvalhttps://modernod.com/news/staar-surgicals-evo-viva-presbyopia-correcting-lens-receives-ce-mark-approval/2477977/STAAR Surgical announced that its EVO Viva presbyopia correcting implantable collamer lens (ICL) has been approved for sale. STAAR received CE Mark approval of the presbyopic indication for its EVO+ Visian ICL with Aspheric (EDOF) Optic, commercially marketed as “EVO Viva,” from its European Noti
- Gilead’s Veklury Gains Conditional EU Approval for Treatment of COVID-19https://modernod.com/news/gileads-veklury-gains-conditional-eu-approval-for-treatment-of-covid-19/2477970/Gilead Sciences said Friday that the European Commission granted conditional approval to Veklury (remdesivir) for the treatment of SARS-CoV-2 infection. The company noted that the clearance, which was based on a rolling review that began in April, follows a
- Santen and Singapore’s Health-Tech Start-up, Plano, Form a Strategic Alliance to Tackle the Global Burden of Myopiahttps://modernod.com/news/santen-and-singapores-health-tech-start-up-plano-form-a-strategic-alliance-to-tackle-the-global-burden-of-myopia/2477947/Santen Pharmaceutical and Plano announced a strategic alliance to tackle the global burden of myopia. Under the alliance, Plano has secured an investment from Santen with the goal of tackling the burden of myopia using both a holistic approach and innovative technological solutions. “
- The FDA Does Not Approve Allergan’s Wet AMD Drug Candidate Abicipar Pegolhttps://modernod.com/news/allergan-and-molecular-partners-receive-complete-response-letter-from-fda-on-biologics-license-application-for-abicipar-pegol/2477937/Citing an unfavorable benefit-risk ratio, the FDA rejected Allergan and co-developer Molecular Partners’ wet AMD drug candidate Abicipar pegol. The FDA issued a complete response letter to the biologics license application (BLA) for Abicipar pegol, a novel, investigational DARPin the
- How Regeneron’s COVID-19 Antibody Cocktail Cuts the Risk of Resistancehttps://modernod.com/news/how-regenerons-covid-19-antibody-cocktail-cuts-the-risk-of-resistance/2477920/When Regeneron said in March that it would speed an antibody treatment into clinical trials for COVID-19, its scientists insisted a cocktail of two antibodies would be more effective than one alone. Now they’re explaining why they chose the two antibodies that moved into human trials last w
- Sherlock Bio Links With Danaher’s IDT to Supply its CRISPR-Based Coronavirus Testhttps://modernod.com/news/sherlock-bio-links-with-danahers-idt-to-supply-its-crispr-based-coronavirus-test/2477877/Sherlock Biosciences will team up with Danaher’s Integrated DNA Technologies division to scale up the manufacturing of its CRISPR-based coronavirus diagnostic test in the coming weeks, according to a FierceBiotech